.Nature Medication, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of patients with HER2+ sophisticated bosom cancer and also energetic or even dependable human brain metastases presented consistent intracranial activity and also wide spread effectiveness of T-DXd.